Lv41
488 积分 2025-05-12 加入
Safety pharmacology 2023 and implementation of the ICH E14/S7B Q&A guidance document
6天前
已完结
How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation
6天前
已完结
Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting
7天前
已完结
Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative
7天前
已完结
Update on the ECG component of the CiPA initiative
7天前
已完结
The hERG potassium channel and hERG screening for drug-induced torsades de pointes
1个月前
已完结
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress
1个月前
已完结
Can the pharmaceutical industry reduce attrition rates?
1个月前
已完结
Drug-Induced Prolongation of the QT Interval
1个月前
已完结
皖公网安备34019202002308
